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Abstract
Human cancer cells typically harbor multiple chromosomal aberrations, nucleotide substitutions 
and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas 
(TCGA) pilot project aims to assess the value of large-scale multidimensional analysis of these 
molecular characteristics in human cancer and to provide the data rapidly to the research 
community. Here, we report the interim integrative analysis of DNA copy number, gene 
expression and DNA methylation aberrations in 206 glioblastomas (GBM), the most common type 
of adult brain cancer, and nucleotide sequence aberrations in 91 of the 206 GBMs. This analysis 
provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the 
PI3 kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered 
in the development of GBM. Furthermore, integration of mutation, DNA methylation and clinical 
treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype 
consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential 
clinical implications. Together, these findings establish the feasibility and power of TCGA, 
demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.
Cancer is a disease of genome alterations: DNA sequence changes, copy number 
aberrations, chromosomal rearrangements, and modification in DNA methylation together 
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drive the development and progression of human malignancies. With the complete 
sequencing of the human genome and continuing improvement of high-throughput genomic 
technologies, it is now feasible to contemplate comprehensive surveys of human cancer 
genomes. The Cancer Genome Atlas (TCGA) aims to catalogue and discover major cancer-
causing genome alterations in large cohorts of human tumors through integrated multi-
dimensional analyses.
The first cancer studied by TCGA is glioblastoma (GBM), the most common primary brain 
tumor in adults 1. Primary GBM, which comprises more than 90% of biopsied or resected 
cases, arises de novo without antecedent history of low grade disease, whereas secondary 
GBM progresses from previously diagnosed low-grade gliomas 1. Patients with newly 
diagnosed GBM have a median survival of approximately one year with generally poor 
responses to all therapeutic modalities 2. Two decades of molecular studies have identified 
important genetic events in human GBMs, including (i) dysregulation of growth factor 
signaling via amplification and mutational activation of receptor tyrosine kinase (RTK) 
genes; (ii) activation of the phosphatidyl inositol 3-kinase (PI3K) pathway; and (iii) 
inactivation of the p53 and retinoblastoma tumor suppressor pathways 1. Recent genome-
wide profiling studies have also shown remarkable genomic heterogeneity among GBM and 
the existence of molecular subclasses within GBM that may, when fully defined, allow 
stratification of treatment 3–8. Albeit fragmentary, such baseline knowledge of GBM 
genetics sets the stage to explore whether novel insights can be gained from a more 
systematic examination of the GBM genome.
Results
As a public resource, all TCGA data are deposited at the Data Coordinating Center (DCC) 
for public access (http://cancergenome.nih.gov/). TCGA data are classified by data type (e.g. 
clinical, mutations, gene expression) and data level to allow structured access to this 
resource with appropriate patient privacy protection. An overview of the data organization is 
provided in Methods, and a detailed description is available in the TCGA Data Primer 
(http://tcga-data.nci.nih.gov/docs/TCGA_Data_Primer.pdf).
Biospecimen collection
Retrospective biospecimen repositories were screened for newly diagnosed GBM based on 
surgical pathology reports and clinical records (Fig. S1). Samples were further selected for 
having matched peripheral blood as well as associated demographic, clinical and 
pathological data (Table S1). Corresponding frozen tissues were reviewed at the 
Biospecimen Core Resource (BCR) to ensure a minimum of 80% tumor nuclei and a 
maximum of 50% necrosis (Fig. S1). DNA and RNA extracted from qualified biospecimens 
were subjected to additional quality control measurements (Methods) prior to distribution to 
TCGA centers for analyses (Fig. S2).
After exclusion based on insufficient tumor content (n=234) and suboptimal nucleic acid 
quality or quantity (n=147), 206 of the 587 biospecimens screened (35%) were qualified for 
copy number, expression, and DNA methylation analyses. Of these, 143 cases had matched 
normal peripheral blood DNAs and were therefore appropriate for re-sequencing. This 
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cohort also included 21 post-treatment GBM cases used for exploratory comparisons (Table 
S1). While it is possible that a small number of progressive secondary GBMs were among 
the remaining 185 cases of newly diagnosed glioblastomas, this cohort represents 
predominantly primary GBM. Indeed, when compared with published cohorts, overall 
survival of the newly diagnosed glioblastoma cases in TCGA is similar to that reported in 
the literature (Fig. S3, p=0.2)9–12.
Genomic and transcriptional aberrations
Genomic copy number alterations (CNAs) were measured on three microarray platforms 
(Methods) and analyzed with multiple analytical algorithms13–15 (Fig. S4; Tables S2–S4). 
Besides the well-known alterations3,13,14, we detected significantly recurrent focal 
alterations not previously reported in GBMs, such as homozygous deletions involving NF1 
and PARK2 and amplifications of AKT3 (Fig. 1a; Tables S2–S4). Search for informative but 
infrequent CNAs also uncovered rare focal events, such as amplifications of FGFR2 and 
IRS2 and deletion of PTPRD (Table S4). Abundances of protein-coding genes and non-
coding microRNA were also measured by transcript-specific and exon-specific probes on 
multiple platforms (Methods, and manuscript in preparation). The resulting integrated gene 
expression data set showed that ~76% of genes within recurrent CNAs have expression 
patterns that correlate with copy number (Table S2). In addition, SNP-based analyses also 
catalogued copy-neutral loss of heterozygosity (LOH), with the most significant region 
being 17p, which contains TP53 (Methods).
Patterns of somatic nucleotide alterations in GBM
91 matched tumor-normal pairs (72 untreated and 19 treated cases) were selected from the 
143 cases for detection of somatic mutations in 601 selected genes (Table S5). The resulting 
sequences, totaling 97 million base pairs (1.1±0.1 million bases per sample), uncovered 453 
validated non-silent somatic mutations(Table S6; http://tcga-data.nci.nih.gov/docs/
somatic_mutations/tcga_mutations.htm). The background mutation rates differed drastically 
between untreated and treated GBMs, averaging 1.4 versus 5.8 somatic silent mutations per 
sample (98 among 72 untreated vs 111 among 19 treated, p<10−21), respectively. This 
difference was predominantly driven by seven hypermutated samples, as determined by 
frequencies of both silent and non-silent mutations (Fig. 1b,c). Four of the 7 hypermutated 
tumors were from patients previously treated with temozolomide and 3 from patients treated 
with CCNU alone or in combination (Table S1b). A hypermutator phenotype in GBM has 
been described in 3 GBM specimens with MSH6 mutations 16,17, prompting us to perform 
a systematic analysis of the genes involved in mismatch repair (MMR). Indeed, 6 of the 7 
hypermutated samples harbored mutations in at least one of the mismatch repair genes 
MLH1, MSH2, MSH6, or PMS2, as compared with only one sample among the 84 non-
hypermutated samples (p = 7×10−8), suggesting a role of decreased DNA repair competency 
in these highly mutated samples derived from treated patients.
By applying a statistical analysis of mutation significance 18, we identified eight genes as 
significantly mutated (false discovery rate (FDR) <10−3) (Fig. 2d, Table S6). Interestingly, 
27 TP53 mutations were detected in the 72 untreated GBMs (37.5%) and 11 mutations in the 
19 treated samples (58%). All of those mutations clustered in the DNA binding domain, a 
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well-known hotspot for p53 mutations in human cancers (Fig. S5; Table S6). Given the 
predominance of primary GBM among this newly diagnosed collection, that result 
unequivocally proves that p53 mutation is a common event in primary GBM.
NF1 is a human glioblastoma suppressor gene—Although somatic mutations in 
NF1 have been reported in a small series of human GBM tumors 21, their role remains 
controversial 22, despite strong genetic data in mouse model systems 19,20. Here, 19 NF1 
somatic mutations were identified in 13 samples (14% of 91), including six nonsense 
mutations, four splice site mutations, five missense changes, and four frameshift indels (Fig. 
2a). Five of these mutations—R1391S (23), R1513* (24), e25 −1 and e29 +1 (25), and 
Q1966* (26)—have been reported as germline alterations in neurofibromatosis patients, thus 
are likely inactivating. In addition, 30 heterozygous deletions in NF1 were observed among 
the entire interim sample set of 206 cases, 6 of which also harbor point mutation (Tables S8 
and S9). Some samples also exhibited loss of expression without evidence of genomic 
alteration (Fig. 2b). Overall, at least 47 of these 206 patient samples (23%) harbored somatic 
NF1 inactivating mutations or deletions, definitively address NF1’s relevance to sporadic 
human GBM.
Prevalence of EGFR family activation—EGFR is frequently activated in primary 
GBMs. Variant III deletion of the extracellular domain (so-called “vIII mutant”)27 has been 
the most commonly described event, in addition to extracellular domain point mutations and 
cytoplasmic domain deletions 28.29. Here, high resolution genomic and exon-specific 
transcriptomic profiling readily detected vIII and C-terminal deletions with correspondingly 
altered transcripts (Fig. 2c). Among the 91 GBM cases with somatic mutation data, 22 
harbored focal amplification of wild type EGFR with no point mutation, 16 had point 
mutations in addition to focal amplification, and three had EGFR point mutations but no 
amplification (Fig. S6; Table S9). Collectively, EGFR alterations were observed in 41 of the 
91 sequenced samples.
ERBB2 mutation has previously been reported in only one GBM tumor 30. In the TCGA 
cohort, 11 somatic ERBB2 mutations in 7 of 91 samples were validated, including 3 in the 
kinase domain and two involving V777A, a site of recurrent missense and in-frame insertion 
mutations in lung, gastric, and colon cancers 31. The remaining eight mutations (including 
seven missense and one splice-site mutation) occurred in the extracellular domain of the 
protein, similar to somatic EGFR substitutions in GBM (Fig. 2d). Unlike in breast cancers, 
focal amplifications of ERBB2 were not observed in GBMs.
Somatic mutations of the PI3K complex in human glioblastoma—The PI3 kinase 
complex is comprised of a catalytically active protein, p110α, encoded by PIK3CA, and a 
regulatory protein, p85α, encoded by PIK3R1. Frequent activating missense mutations of 
PIK3CA have been reported in multiple tumor types, including GBM32,33. These mutations 
occur primarily in the adaptor binding domain (ABD) as well as the C2 helical and kinase 
domains 34–36. Indeed, PIK3CA somatic nucleotide substitutions were detected in six of the 
91 sequenced samples (Table S6). Besides the 4 matching events already reported in the 
COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/), two novel in-frame 
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deletions were detected in the ABD of PIK3CA (“L10del” and “P17del”). Those deletions 
may disrupt interactions between p110α and its regulatory subunit, p85α 37.
Unlike PIK3CA, PIK3R1 has rarely been reported as mutated in cancers. Among the five 
reported PIK3R1 nucleotide substitutions in cancers 38,39, one was in a glioblastoma 39. In 
our TCGA cohort, 9 PIK3R1 somatic mutations were detected among the 91 sequenced 
GBMs. None of them was in samples with PIK3CA mutations. Of the nine mutations, eight 
lay within the intervening SH2 (or iSH2) domain and four are 3-basepair in-frame deletions 
(Fig. 3a and Table S6). In accord with the crystal structure of PI3 kinase, which identifies 
the D560 and N564 amino acid residues in p85α as contact points with the N345 amino acid 
residue in the C2 domain of p110α37, the mutations detected in GBM cluster around those 
three amino acid residues (Fig. 3b), including a N345K mutation in PIK3CA (previously 
reported in colon and breast cancers 40) and two novel D560 mutations in PIK3R1 (D560Y 
and N564K). We also identified an 18-basepair deletion spanning residues D560 to S565 
(DKRMNS) in PIK3R1 (Fig. 3b) in addition to three other novel deletions (R574del, 
T576del, and W583del) in proximity to the 3 key residues. We speculate that spatial 
constraints due to these deletions might prevent inhibitory contact of p85α nSH2 with the 
helical domain of p110α, causing constitutive PI3K activity. Taken together, the pattern of 
clustering of the mutations around key residues defined by the crystal structure of PI3K 
strongly suggest that these novel PIK3R1 point mutations and insertions/deletions disrupt 
the important C2-iSH2 interaction, relieving the inhibitory effect of p85α on p110α.
MGMT methylation and MMR proficiency in post-treatment GBMs
Cancer-specific DNA methylation of CpG dinucleotides located in CpG islands within the 
promoters of 2,305 genes were measured relative to normal brain DNA (Table S7; 
Methods). The promoter methylation status of MGMT, a DNA repair enzyme that removes 
alkyl groups from guanine residues 41, is associated with GBM sensitivity to alkylating 
agents 42,43. Among the 91 sequenced cases, 19 samples were found to contain MGMT 
promoter methylation (including 13 of the 72 untreated and 6 of the 19 treated cases). When 
juxtaposed with somatic mutation data, an intriguing relationship between the hypermutator 
phenotype and MGMT methylation status emerged in the treated samples. Specifically, 
MGMT methylation was associated with a profound shift in the nucleotide substitution 
spectrum of treated GBMs (Fig. 4a). Among the treated samples lacking MGMT methylation 
(n=13), 29% (29/99) of the validated somatic mutations occurred as G:C to A:T transitions 
in CpG dinucleotides (characteristic of spontaneous deamination of methylated cytosines), 
and a comparable 23% (23/99) of all mutations occurred as G:C to A:T transitions in non-
CpG dinucleotides. In contrast, in the treated samples with MGMT methylation (n=6), 81% 
of all mutations (146/181) turned out to be of the G:C to A:T transition type in non-CpG 
dinucleotides whereas only 4% (8/181) of all mutations were G:C to A:T transition 
mutations within CpGs. That pattern is consistent with a failure to repair alkylated guanine 
residues caused by treatment. In other words, MGMT methylation shifted the mutation 
spectrum of treated samples to a preponderance of G:C to A:T transition at non-CpG sites.
Significantly, the mutational spectra in the mismatch repairs (MMR) genes themselves 
reflected MGMT methylation status and treatment consequences. All seven mutations in 
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MMR genes found in six MGMT methylated hypermutated (treated) tumors occurred as G:C 
to A:T mutations at non-CpG sites (Fig. 4b; Table S6), while neither MMR mutations in 
non-methylated hypermutated tumors was of this characteristic. Hence, these data show that 
MMR deficiency and MGMT methylation together, in the context of treatment, exert a 
powerful influence on the overall frequency and pattern of somatic point mutations in GBM 
tumors, an observation of potential clinical importance.
Integrative analyses define core pathways required for GBM pathogenesis
To begin to construct an integrated view of common genetic alterations in the GBM 
genome, we mapped the unequivocal genetic alterations—validated somatic nucleotide 
substitutions, homozygous deletions and focal amplifications—onto major pathways 
implicated in GBM 1. That analysis identified a highly interconnected network of 
aberrations (Figs. S7–S8), including three major pathways: receptor tyrosine kinases (RTKs) 
signaling, and the p53/RB tumor suppressor pathways (Fig. 5).
By copy number data alone, 66%, 70% and 59% of the 206 samples harbored somatic 
alterations of the RB, TP53 and RTK pathways, respectively (Table S8). In the 91 samples 
for which there was also sequencing data, the frequencies of somatic alterations increased to 
87%, 78% and 88%, respectively (Table S9). There was a statistical tendency toward mutual 
exclusivity of alterations of components within each pathway (p-values of 9.3×10−10, 
2.5×10−13, and 0.022, respectively for the p53, RB, and RTK pathways; Tables S10), 
consistent with the thesis that deregulation of one component in the pathway relieves the 
selective pressure for additional ones. However, we observed a greater than random chance 
(one-tailed p = 0.0018) that a given sample harbors at least one aberrant gene from each of 
the three pathways (Table S10). In fact, 74% harbored aberrations in all three pathways, a 
pattern suggesting that deregulation of the three pathways is a core requirement for 
glioblastoma pathogenesis.
Besides frequent deletions and mutations of the PTEN lipid phosphatase tumor suppressor 
gene, 86% of the GBM samples harbored at least one genetic event in the core RTK/PI3K 
pathway (Fig. 5a). In addition to EGFR and ERBB, PDGFRA (13%) and MET (4%) showed 
frequent aberrations (Tables S9). 10 of the 91 sequenced samples have amplifications or 
point mutations in at least two of the four RTKs catalogued (EGFR, ERBB2, PDGFRA and 
MET) (Table S9), suggesting genomic activation can be a mechanism for co-activated RTKs 
44.
Inactivation of the p53 pathway occurred in the form of ARF deletions (55%), amplifications 
of MDM2 (11%) and MDM4 (4%), in addition to mutations of p53 itself (Fig. 5b; Table S8). 
Among 91 sequenced samples (Table S9), genetic lesions in TP53 were mutually exclusive 
of those in MDM2 or MDM4 (odds ratios of 0.00 for both; p = 0.02 and 0.068, respectively; 
Tables S10), but not of those in ARF. In fact, 10 of the 32 tumors with TP53 mutations also 
deleted ARF, suggesting that homozygous deletion of the CDKN2A locus (which encodes 
both p16INK4A and ARF) was at least in part driven by p16INK4A.
Among the 77% samples harboring RB pathway aberrations (Fig. 5c), the most common 
event was deletion of the CDKN2A/CDKN2B locus on chromosome 9p21 (55% and 53%), 
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followed by amplification of the CDK4 locus (14%) (Fig. 1a; Table S8 and S9). Although 
copy number alterations in the CDK/RB pathway members can co-occur in the same tumor 
14, all nine samples with RB1 nucleotide substitutions (Table S9) lacked CDKN2A/B 
deletion or other copy number alterations in the pathway, suggesting that inactivation of 
RB1 by nucleotide substitution, in contrast to copy number loss, obviates the genetic 
pressure for activation of upstream cyclin/cyclin-dependent kinases..
Discussion
In establishing this pilot program, TCGA has developed important principles in biospecimen 
banking and collection (manuscript in preparation), and established the infrastructure that 
will serve similar efforts in the future. Although it ensured high quality data, the stringent 
biospecimen selection criteria may have introduced a degree of bias because small samples 
and samples with high levels of necrosis were excluded. Nonetheless, the clinical parameters 
of this cohort are similar to other published cohorts (Table S1; Fig. S3).
The integrated analyses of multi-dimensional genomic data from complementary technology 
platforms have proved informative. In addition to pinpointing deregulation of RB, p53 and 
RTK/RAS/PI3K pathways as obligatory events in most, and perhaps all, GBM tumors, the 
patterns of mutations may also inform future therapeutic decisions. It would be reasonable to 
speculate that patients with deletions or inactivating mutations in CDKN2A or CDKN2C or 
patients with amplifications of CDK4/CDK6 would be candidates for treatment with CDK 
inhibitors, a strategy not likely to be effective in patients with RB1 mutation. Similarly, 
patients with PTEN deletions or activating mutations in PIK3CA or PIK3R might be 
expected to benefit from a PI3 kinase or PDK1 inhibitor, while tumors in which the PI3 
kinase pathway is altered by AKT3 amplification might prove refractory to those modalities. 
The presence of genomic co-amplification reinforces the recent report of multiple 
phosphorylated (activated) RTKs in individual GBM specimens 44, suggesting a way to 
tailor anti-RTK therapeutic cocktails to specific patterns of RTK mutation. In addition, 
combination anti-RTK therapy might synergize with downstream inhibition of PI3K or cell 
cycle mediators. In contrast, GBMs with NF1 mutations might benefit from a RAF or MEK 
inhibitor as part of a combination, as shown for BRAF mutant cancers 45.
One of the most important biomarkers for GBM is the methylation status of MGMT, which 
predicts sensitivity to temozolomide 42,43, an alkylating agent that is the current standard of 
care for GBM patients. Integrative analysis of mutation, DNA methylation and clinical 
(treatment) data, albeit with small sample numbers, suggests a series of inter-related events 
that may impact clinical response and outcome. Newly diagnosed glioblastomas with 
MGMT methylation respond well to treatment with alkylating agents, in part as a 
consequence of unrepaired alkylated guanine residues initiating cycles of futile mismatch 
repair, which can lead to cell death 46–48. Therefore, treatment of MGMT-deficient GBMs 
with alkylating therapy introduces a strong selective pressure to lose mismatch repair 
function 49. That conclusion is consistent with our observation that the mismatch repair 
genes themselves are mutated with characteristic C:G → A:T transitions at non-CpG sites 
resulting from unrepaired alkylated guanine residues. Thus, initial methylation of MGMT, in 
conjunction with treatment, may lead to both a shift in mutation spectrum affecting 
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mutations at mismatch repair genes and selective pressure to lose mismatch repair function. 
In other words, our finding raises the possibility that patients who initially respond to the 
frontline therapy in use today may evolve not only treatment resistance, but also an MMR-
defective hypermutator phenotype. If such a mechanism indeed underlies emergence of 
MMR-defective resistance, one may speculate that selective strategies targeting mismatch-
repair deficiency 50 would represent a rational upfront combination that may prevent or 
minimize emergence of such resistance. Validation of this hypothesis will have immediate 
clinical impact and implication for therapeutic design. For one, it suggests that treatment 
mediated mutator phenotype may lead to pathway mutations that confer resistance to new 
targeted therapies thereby raising the concern that combined or serial treatment with 
alkylating agents and pathway targeted therapies may substantially increase the probability 
of developing resistance to such targeted drugs.
In conclusion, the power of TCGA to produce unprecedented multi-dimensional data sets 
employing statistically robust numbers of samples sets the stage for a new era in the 
discovery of new cancer interventions. The integrative analyses leading to formulation of an 
unanticipated hypothesis on a potential mechanism of resistance highlights precisely the 
value and power of such project design, demonstrating how unbiased and systematic cancer 
genome analyses of large sample cohorts can lead to paradigm-shifting discoveries.
Method Summary
Biospecimens were screened from retrospective banks of Tissue Source Sites under 
appropriate IRB approvals for newly diagnosed GBM with minimal 80% tumor cell 
percentage. RNA and DNA extracted from qualified specimens were distributed to TCGA 
centers for analysis. Whole genome-amplified genomic DNA samples from tumors and 
normals were sequenced by the Sanger method. Mutations were called, verified using a 
second genotyping platform, and systematically analyzed to identify significantly mutated 
genes after correcting for the background mutation rate for nucleotide type and the sequence 
coverage of each gene. DNA copy number analyses were performed using the Agilent 244K, 
Affymetrix SNP6.0, and Illumina 550K DNA copy number platforms. Sample-specific and 
recurrent copy number changes were identified using various algorithms (GISTIC, GTS, 
RAE). mRNA and miRNA expression profiles were generated using Affymetrix U133A, 
Affymetrix Exon 1.0 ST, custom Agilent 244K, and Agilent miRNA array platforms. 
mRNA expression profiles were integrated into a single estimate of relative gene expression 
for each gene in each sample. Methylation at CpG dinucelotides was measured using the 
Illumina GoldenGate assay. All data for DNA sequence alterations, copy number, mRNA 
expression, miRNA expression, and CpG methylation were deposited in standard common 
formats in the TCGA DCC at http://cancergenome.nih.gov/dataportal/. All archives 
submitted to DCC were validated to ensure a common document structure and to ensure 
proper use of identifying information.
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The Cancer Genome Atlas (TCGA) Research Network
Tissue Source Sites
Duke University Medical School—Roger McLendon(6), Allan Friedman(7), Darrell 
Bigner(6), Emory University: Erwin G Van Meir(45,46,47), Daniel J Brat(47,48), Gena 
Marie Mastrogianakis(45), Jeffrey J Olson(45,46,47) Henry Ford Hospital: Tom 
Mikkelsen(8), Norman Lehman(50), MD Anderson Cancer Center: Ken Aldape(10), W.K. 
Alfred Yung(11), Oliver Bogler(12), University of California San Francisco: Scott 
VandenBerg(9), Mitchel Berger(51), Michael Prados(51)
Genome Sequencing Centers
Baylor College of Medicine—Donna Muzny(34), Margaret Morgan(34), Steve 
Scherer(34), Aniko Sabo(34), Lynn Nazareth(34), Lora Lewis(34), Otis Hall(34), Yiming 
Zhu(34), Yanru Ren(34), Omar Alvi(34), Jiqiang Yao(34), Alicia Hawes(34), Shalini 
Jhangiani(34), Gerald Fowler(34), Anthony San Lucas(34), Christie Kovar(34), Andrew 
Cree(34), Huyen Dinh(34), Jireh Santibanez(34), Vandita Joshi(34), Manuel L. Gonzalez-
Garay(34), Christopher A. Miller(34,36), Aleksandar Milosavljevic(34,36,37), Larry 
Donehower(35), David A. Wheeler(34), Richard A. Gibbs(34), Broad Institute of MIT and 
Harvard: Kristian Cibulskis(52), Carrie Sougnez(53), Tim Fennell(54), Scott Mahan(59), 
Jane Wilkinson(55), Liuda Ziaugra(56), Robert Onofrio(56), Toby Bloom(57), Rob 
Nicol(58), Kristin Ardlie(59), Jennifer Baldwin(55), Stacey Gabriel(56), Eric 
Lander(4,60,61), Washington University in Saint Louis: Li Ding(19), Robert S. Fulton(19), 
Michael D. McLellan(19), John Wallis(19), David E. Larson(19), Xiaoqi Shi(19), Rachel 
Abbott(19), Lucinda Fulton(19), Ken Chen(19), Daniel C. Koboldt(19), Michael C. 
Wendl(19), Rick Meyer(19), Yuzhu Tang(19), Ling Lin(19), John R. Osborne(19), Brian H. 
Dunford-Shore(19), Tracie L. Miner(19), Kim Delehaunty(19), Chris Markovic(19), Gary 
Swift(19), William Courtney(19), Craig Pohl(19), Scott Abbott(19), Amy Hawkins(19), 
Shin Leong(19), Carrie Haipek(19), Heather Schmidt(19), Maddy Wiechert(19), Tammi 
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Figure 1. Significant copy number aberrations and pattern of somatic mutations
(a) Frequency and significance of focal high-level copy-number alterations. Known and 
putative target genes are listed for each significant CNA, with “Number of Genes” denoting 
the total number of genes within each focal CNA boundary.
(b–c) Distribution of the number of (b) silent and (c) non-silent mutations across the 91 
GBM samples separated according to their treatment status, showing hypermutation in 7 out 
of the 19 treated samples.
(d) Significantly mutated genes in 91 glioblastomas. The eight genes attaining a false 
discovery rate <0.1 are displayed here. Somatic mutations occurring in untreated samples 
are in dark blue; those found in statistically non-hypermutated and hypermutated samples 
among the treated cohort are in respectively lighter shades of blue.
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Figure 2. Mutations in NF1 tumor suppressor gene and EGFR family members
(a) NF1 somatic mutations in 91 glioblastoma tumors. Both missense mutations and 
truncating nonsense, frameshift, and splice site mutations were observed. Splice positions 
are given in number of bases to the closest exon (e#) numbered according to the NF1 
reference transcript in the Human Gene Mutation Database; positive = 3′ of exon, negative = 
5′ of exon. *: stop codon. fs: frameshift.
(b) Correlation of copy number and mutation status at the NF1 locus with level of 
expression (Y axis). Mutation events predicted to result in fewer expressed copies (including 
deletion, nonsense, splice site, and frameshift mutations) generally have lower observed 
expression. HomoDel = homozygous deletion; HemiDel = single-copy loss; Neutral = no 
change in copy number (presumed diploid); Amp = increased copy number. Copy number 
status of the NF1 locus in each sample was determined as described in the Supplementary 
Information.
(c). DNA Copy number and mRNA expression profiles for TCGA samples TCGA-08–0356 
(red), TCGA-02–0064 (blue), and TCGA-02–0529 (green) at the EGFR locus. The upper 
panel shows the segmented DNA copy number (based on Affymetrix SNP6.0 data) versus 
genomic coordinates on chromosome 7. The lower panel shows relative exon expression 
levels across the known EGFR exons from the Affymetrix Exon array ordered by genomic 
position, where relative expression is the median-centered difference in exon intensity and 
gene intensity. The EGFR gene model lies between the two plots. Black lines map the 
genomic positions of exons 2 through 7 and 26 through 28. Note that structural deletions 
cause the relatively lower expression of exons 2–7 in the green and blue samples and exons 
26–28 in the red sample.
(d) ERBB2 somatic mutations in 91 glioblastoma tumors. Mutations cluster in the 
extracellular domain in both genes. Splice site mutation position is given in number of bases 
to the closest exon (e#); positive = 3′ of exon.
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Figure 3. PIK3R1 and PIK3CA mutations in GBM
(a). Diamonds above the backbone indicate the locations of mutations found in TCGA 
tumors. ABD: adaptor binding domain; RDB: Ras binding domain; C2: membrane-binding 
domain; iSH2: intervening domain.
(b). Four mutations found in the interaction interface of the p110α; C2 domain with iSH2 of 
p85 α. Two residues of p85 α, D560 and N564, are within hydrogen-bonding distance of the 
C2 residue of p110 α, N345.
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Figure 4. Pattern of somatic mutations, MGMT DNA methylation, and MMR gene mutations in 
treated GBMs
(a). The mean number of validated somatic nucleotide substitutions per tumor for key 
sample groups is indicated on the Y-axis and denoted by the height of the bar histograms. 
Samples are grouped along the X-axis according to treatment status of the patient (− = 
untreated; + = treated), DNA methylation status of MGMT (meth = DNA methylated; − = 
not methylated), and genetic status of MMR genes − = no genes mutated and mut = one or 
more of the MLH1, MSH2, MSH6, or PMS2 genes mutated); the number below each bar 
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indicates the number of samples in the group. Bars are color-coded for types of nucleotide 
substitutions including G-to-A transitions at non-CpG sites (orange), G-to-A transitions at 
CpG sites (blue), and other mutation types (green).
(b). Bar histogram for mutation spectrum in the MMR genes as a function of treatment 
status, and methylation status of MGMT. The color code for substitution types is the same as 
in (a).
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Figure 5. Frequent genetic alterations in three critical signaling pathways
Primary sequence alterations and significant copy number changes for components of the (a) 
RTK/RAS/PI-3K, (b) p53, and (c) RB signaling pathways are shown. Red indicates 
activating genetic alterations, with frequently altered genes showing deeper shades of red. 
Conversely, blue indicates inactivating alterations, with darker shades corresponding to a 
higher percentage of alteration. For each altered component of a particular pathway, the 
nature of the alteration and the percentage of affected tumors affected are indicated. Blue 
boxes contain the final percentages of glioblastomas with alterations in at least one known 
component gene of the designated pathway.
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